Stock Market News
Alliance Pharma's pregnancy sickness treatment set for approval
Specialist pharmaceutical firm Alliance Pharma on Thursday completed its UK regulatory application for its in-licensed drug Diclectin, a prescription treatment for nausea and vomiting during pregnancy.
The AIM traded company said it anticipates the launch of Diclectin to take place in autumn following issue of the formal marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) in the coming weeks.
The product, which has a proven safety and efficacy profile, was in-licensed from Canada's Duchesnay for the UK in 2015 and for a further nine European territories in 2016.
Peter Butterfield, chief executive of Alliance Pharma, said: "There are currently no licensed treatments for nausea and vomiting of pregnancy in the UK, highlighting a clear unmet need for patients and clinicians. For Alliance, Diclectin represents a sizeable mid-term opportunity and also allows us to further leverage our European footprint."
The treatment has been prescribed to over 30m women in Canada over the 40 years it has been in use and, since 2013, has been approved in the US, South Korea, Singapore and Israel.
Duchesnay, which calculates that nausea and vomiting of pregnancy can affect up to 80% of all pregnant women, said it was continuing to support Alliance in their efforts to provide a licensed treatment.
Alliance said that once formal approval is granted in the UK it will seek regulatory approvals for other European territories ahead of planned international launches in 2019.
As of 1010 BST, Alliance Pharma's shares were up 4.44% at 94.00p.
The AIM traded company said it anticipates the launch of Diclectin to take place in autumn following issue of the formal marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) in the coming weeks.
The product, which has a proven safety and efficacy profile, was in-licensed from Canada's Duchesnay for the UK in 2015 and for a further nine European territories in 2016.
Peter Butterfield, chief executive of Alliance Pharma, said: "There are currently no licensed treatments for nausea and vomiting of pregnancy in the UK, highlighting a clear unmet need for patients and clinicians. For Alliance, Diclectin represents a sizeable mid-term opportunity and also allows us to further leverage our European footprint."
The treatment has been prescribed to over 30m women in Canada over the 40 years it has been in use and, since 2013, has been approved in the US, South Korea, Singapore and Israel.
Duchesnay, which calculates that nausea and vomiting of pregnancy can affect up to 80% of all pregnant women, said it was continuing to support Alliance in their efforts to provide a licensed treatment.
Alliance said that once formal approval is granted in the UK it will seek regulatory approvals for other European territories ahead of planned international launches in 2019.
As of 1010 BST, Alliance Pharma's shares were up 4.44% at 94.00p.
Related share prices |
---|
Alliance Pharma (APH) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price